AB0214 Octreotide Ameliorates Dermal Fibrosis in Bleomycin-Induced Scleroderma
BackgroundInsulin like growth factor-I (IGF-I) is a potent differentiation and growth factor. Its level has been demonstrated to enhance in bronchoalveolar lavage fluid harvested from scleroderma patient with pulmonary fibrosis. Moreover, increased serum and tissue IGF-I levels has also been shown,...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 74; no. Suppl 2; pp. 962 - 963 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.06.2015
|
Online Access | Get full text |
Cover
Loading…
Abstract | BackgroundInsulin like growth factor-I (IGF-I) is a potent differentiation and growth factor. Its level has been demonstrated to enhance in bronchoalveolar lavage fluid harvested from scleroderma patient with pulmonary fibrosis. Moreover, increased serum and tissue IGF-I levels has also been shown, in patient with morphea. On the other hand, anti-fibrotic action of octreotide has been reported in bleomycin (BLM)-induced pulmonary fibrosis model and in patients with idiopathic pulmonary fibrosis.ObjectivesThe aim of the present study was to research potential prophylactic and therapeutic effects of octreotide on the BLM-induced experimental scleroderma model.Methods60 Balb/c female mice were included in the study. They were divided 6 groups as prophylactic-early (group I [control I], group II [sham I] and group III [octreotide I]) and therapeutic-late (group IV [control II], group V [sham II] and group VI [octreotide II]) groups. Phosphate buffered saline (PBS) was injected subcutaneously and daily to shaved upper back skin in the control groups (groups I and IV). Daily subcutaneous BLM (100 mg BLM dissolved in 100 ml PBS for each mouse) was injected to shaved upper back skin for three weeks in the groups II and III, and for 6 weeks in the groups V and VI. The groups II and V were placebo (sham) groups. In addition to BLM, octreotide (100 μg/kg/day for each mouse) was injected subcutaneously to dorsal fornt of neck, for first three weeks in the group III (prophylactic 100 μg/kg), and second three weeks in the group VI (therapeutic 100 μg/kg)Mice in the groups I, II and III (prophylactic application groups) were sacrificed at the end of third week, while groups IV, V and VI (therapeutic application groups) mice were sacrificed at the end of 6th week. Skin tissue samples were harvested for histological and real-time PCR (RT-PCR) analysis. Tissue mRNA expressions of TGF-β1, fibronectin-1, IGFBP3 and IGFBP5 were evaluated by RT-PCR.ResultsRepeated BLM applications increased dermal inflammatory cell counts (Figure 1A), dermal thickness (Figure 1B) and led to dermal fibrosis at both third and 6th weeks. Moreover, mRNA expressions of TGF-β1, fibronectin-1, IFBP3 and IGFBP5 were higher in the BLM-injected sham groups compared to their controls (p<0.05 for all). On the other hand, TGF-β1, fibronectin-1, IFBP3 and IGFBP5 mRNA expressions were significantly decreased in both prophylactic and therapeutic octreotide groups compared to the own sham groups (p<0.05 for all). Similarly, in both prophylactic and therapeutic applications of octreotide decreased dermal inflammatory infiltrations and dermal thickness (Figure 1).Figure 1.Dermal inflammatory cell counts (A) and dermal thicknesses (B) in the study groups.ConclusionsThe present study documents that octreotide has anti-fibrotic actions on experimentally induced dermal fibrosis. It can be suggested that IGF-I plays pathogenic roles and octreotide is candidate to research in the treatment of scleroderma.ReferencesVeraldi, Feghali-Bostwick CA. Open Rheumatol J. 2012;6:140-5.Crestani B, et al. Eur Respir J. 2012;39(3):772-5.Disclosure of InterestNone declared |
---|---|
AbstractList | Background Insulin like growth factor-I (IGF-I) is a potent differentiation and growth factor. Its level has been demonstrated to enhance in bronchoalveolar lavage fluid harvested from scleroderma patient with pulmonary fibrosis. Moreover, increased serum and tissue IGF-I levels has also been shown, in patient with morphea. On the other hand, anti-fibrotic action of octreotide has been reported in bleomycin (BLM)-induced pulmonary fibrosis model and in patients with idiopathic pulmonary fibrosis. Objectives The aim of the present study was to research potential prophylactic and therapeutic effects of octreotide on the BLM-induced experimental scleroderma model. Methods 60 Balb/c female mice were included in the study. They were divided 6 groups as prophylactic-early (group I [control I], group II [sham I] and group III [octreotide I]) and therapeutic-late (group IV [control II], group V [sham II] and group VI [octreotide II]) groups. Phosphate buffered saline (PBS) was injected subcutaneously and daily to shaved upper back skin in the control groups (groups I and IV). Daily subcutaneous BLM (100 mg BLM dissolved in 100 ml PBS for each mouse) was injected to shaved upper back skin for three weeks in the groups II and III, and for 6 weeks in the groups V and VI. The groups II and V were placebo (sham) groups. In addition to BLM, octreotide (100 μg/kg/day for each mouse) was injected subcutaneously to dorsal fornt of neck, for first three weeks in the group III (prophylactic 100 μg/kg), and second three weeks in the group VI (therapeutic 100 μg/kg) Mice in the groups I, II and III (prophylactic application groups) were sacrificed at the end of third week, while groups IV, V and VI (therapeutic application groups) mice were sacrificed at the end of 6th week. Skin tissue samples were harvested for histological and real-time PCR (RT-PCR) analysis. Tissue mRNA expressions of TGF-β1, fibronectin-1, IGFBP3 and IGFBP5 were evaluated by RT-PCR. Results Repeated BLM applications increased dermal inflammatory cell counts ( Figure 1A ), dermal thickness ( Figure 1B ) and led to dermal fibrosis at both third and 6th weeks. Moreover, mRNA expressions of TGF-β1, fibronectin-1, IFBP3 and IGFBP5 were higher in the BLM-injected sham groups compared to their controls (p<0.05 for all). On the other hand, TGF-β1, fibronectin-1, IFBP3 and IGFBP5 mRNA expressions were significantly decreased in both prophylactic and therapeutic octreotide groups compared to the own sham groups (p<0.05 for all). Similarly, in both prophylactic and therapeutic applications of octreotide decreased dermal inflammatory infiltrations and dermal thickness ( Figure 1 ). Conclusions The present study documents that octreotide has anti-fibrotic actions on experimentally induced dermal fibrosis. It can be suggested that IGF-I plays pathogenic roles and octreotide is candidate to research in the treatment of scleroderma. References Veraldi, Feghali-Bostwick CA. Open Rheumatol J. 2012;6:140-5. Crestani B, et al. Eur Respir J. 2012;39(3):772-5. Disclosure of Interest None declared BackgroundInsulin like growth factor-I (IGF-I) is a potent differentiation and growth factor. Its level has been demonstrated to enhance in bronchoalveolar lavage fluid harvested from scleroderma patient with pulmonary fibrosis. Moreover, increased serum and tissue IGF-I levels has also been shown, in patient with morphea. On the other hand, anti-fibrotic action of octreotide has been reported in bleomycin (BLM)-induced pulmonary fibrosis model and in patients with idiopathic pulmonary fibrosis.ObjectivesThe aim of the present study was to research potential prophylactic and therapeutic effects of octreotide on the BLM-induced experimental scleroderma model.Methods60 Balb/c female mice were included in the study. They were divided 6 groups as prophylactic-early (group I [control I], group II [sham I] and group III [octreotide I]) and therapeutic-late (group IV [control II], group V [sham II] and group VI [octreotide II]) groups. Phosphate buffered saline (PBS) was injected subcutaneously and daily to shaved upper back skin in the control groups (groups I and IV). Daily subcutaneous BLM (100 mg BLM dissolved in 100 ml PBS for each mouse) was injected to shaved upper back skin for three weeks in the groups II and III, and for 6 weeks in the groups V and VI. The groups II and V were placebo (sham) groups. In addition to BLM, octreotide (100 μg/kg/day for each mouse) was injected subcutaneously to dorsal fornt of neck, for first three weeks in the group III (prophylactic 100 μg/kg), and second three weeks in the group VI (therapeutic 100 μg/kg)Mice in the groups I, II and III (prophylactic application groups) were sacrificed at the end of third week, while groups IV, V and VI (therapeutic application groups) mice were sacrificed at the end of 6th week. Skin tissue samples were harvested for histological and real-time PCR (RT-PCR) analysis. Tissue mRNA expressions of TGF-β1, fibronectin-1, IGFBP3 and IGFBP5 were evaluated by RT-PCR.ResultsRepeated BLM applications increased dermal inflammatory cell counts (Figure 1A), dermal thickness (Figure 1B) and led to dermal fibrosis at both third and 6th weeks. Moreover, mRNA expressions of TGF-β1, fibronectin-1, IFBP3 and IGFBP5 were higher in the BLM-injected sham groups compared to their controls (p<0.05 for all). On the other hand, TGF-β1, fibronectin-1, IFBP3 and IGFBP5 mRNA expressions were significantly decreased in both prophylactic and therapeutic octreotide groups compared to the own sham groups (p<0.05 for all). Similarly, in both prophylactic and therapeutic applications of octreotide decreased dermal inflammatory infiltrations and dermal thickness (Figure 1).Figure 1.Dermal inflammatory cell counts (A) and dermal thicknesses (B) in the study groups.ConclusionsThe present study documents that octreotide has anti-fibrotic actions on experimentally induced dermal fibrosis. It can be suggested that IGF-I plays pathogenic roles and octreotide is candidate to research in the treatment of scleroderma.ReferencesVeraldi, Feghali-Bostwick CA. Open Rheumatol J. 2012;6:140-5.Crestani B, et al. Eur Respir J. 2012;39(3):772-5.Disclosure of InterestNone declared |
Author | Ozercan, I.H. Orhan, S.O. Koca, S.S. Yolbas, S. Tektemur, A. Onalan, E. Yildirim, A. |
Author_xml | – sequence: 1 givenname: S.O. surname: Orhan fullname: Orhan, S.O. organization: Department Of Rheumatology, Faculty Of Medicine, Firat University – sequence: 2 givenname: S. surname: Yolbas fullname: Yolbas, S. organization: Department Of Rheumatology, Faculty Of Medicine, Firat University – sequence: 3 givenname: A. surname: Yildirim fullname: Yildirim, A. organization: Department Of Rheumatology, Faculty Of Medicine, Firat University – sequence: 4 givenname: A. surname: Tektemur fullname: Tektemur, A. organization: Department of Medical Biology – sequence: 5 givenname: I.H. surname: Ozercan fullname: Ozercan, I.H. organization: Department of Pathology, Faculty Of Medicine, Firat University, Elazig, Turkey – sequence: 6 givenname: E. surname: Onalan fullname: Onalan, E. organization: Department of Medical Biology – sequence: 7 givenname: S.S. surname: Koca fullname: Koca, S.S. organization: Department Of Rheumatology, Faculty Of Medicine, Firat University |
BookMark | eNqVkLFOwzAQhi1UJNrCO0TqnHJ2YicWU1soVEIqEjBbdnIRrhKn2M3QjYUX5UlIKAMr0-nu_v_-0zchI9c6JGRGYU5pIq61c_4Nu6a0IWZAeYxdrf2cpwmckTFNRd6PBYzIGACSOJUiuyCTEHZ9CznNx-RpsQRG06-Pz21x8NgebInRosHatl4fMES36BtdR2trfBtsiKyLljW2zbGwLt64siuwjJ6LGn1bDtJLcl7pOuDVb52S1_Xdy-ohftzeb1aLx9hQlqWxrDhDzYHJLDMALDEcZC7ypBKQAcsTbgwKxiuDEqnkSSG11MIYRmUm-_2UzE5397597zAc1K7tvOsjFZVAs0xCj2FKbk6qov8-eKzU3ttG-6OioAaE6g9CNSBUPwjVgLB3i5PbNLt_Gb8B53l93A |
CODEN | ARDIAO |
ContentType | Journal Article |
Copyright | 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
Copyright_xml | – notice: 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
DBID | AAYXX CITATION 3V. 7X7 7XB 88E 88I 8AF 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9- K9. LK8 M0R M0S M1P M2P M7P PQEST PQQKQ PQUKI PRINS Q9U |
DOI | 10.1136/annrheumdis-2015-eular.5430 |
DatabaseName | CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection BMJ Journals ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Biological Sciences Consumer Health Database Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database Biological Science Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic |
DatabaseTitle | CrossRef ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest Central Student |
Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2060 |
EndPage | 963 |
ExternalDocumentID | 4322501969 10_1136_annrheumdis_2015_eular_5430 |
GroupedDBID | --- .55 .GJ .VT 0R~ 23M 2WC 39C 3O- 3V. 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOFX ACPRK ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FRP FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IGG IHR INH INR IOF J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PQQKQ PROAC PSQYO Q2X R53 RHF RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP AAYXX CITATION ITC 7XB 8FK K9. PQEST PQUKI PRINS Q9U |
ID | FETCH-LOGICAL-b1274-9f52ea502977b0023b5098683f60702835bbe625fbe9e1953c9a9a6bb21979283 |
IEDL.DBID | BENPR |
ISSN | 0003-4967 |
IngestDate | Thu Oct 10 18:22:53 EDT 2024 Thu Sep 26 18:52:44 EDT 2024 Wed Aug 21 03:27:42 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b1274-9f52ea502977b0023b5098683f60702835bbe625fbe9e1953c9a9a6bb21979283 |
PQID | 1901779054 |
PQPubID | 2041045 |
PageCount | 2 |
ParticipantIDs | proquest_journals_1901779054 crossref_primary_10_1136_annrheumdis_2015_eular_5430 bmj_primary_10_1136_annrheumdis_2015_eular_5430 |
PublicationCentury | 2000 |
PublicationDate | 20150600 2015-06-00 20150601 |
PublicationDateYYYYMMDD | 2015-06-01 |
PublicationDate_xml | – month: 06 year: 2015 text: 20150600 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Annals of the rheumatic diseases |
PublicationYear | 2015 |
Publisher | BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group LTD |
SSID | ssj0000818 |
Score | 2.1950111 |
Snippet | BackgroundInsulin like growth factor-I (IGF-I) is a potent differentiation and growth factor. Its level has been demonstrated to enhance in bronchoalveolar... Background Insulin like growth factor-I (IGF-I) is a potent differentiation and growth factor. Its level has been demonstrated to enhance in bronchoalveolar... |
SourceID | proquest crossref bmj |
SourceType | Aggregation Database Publisher |
StartPage | 962 |
Title | AB0214 Octreotide Ameliorates Dermal Fibrosis in Bleomycin-Induced Scleroderma |
URI | http://dx.doi.org/10.1136/annrheumdis-2015-eular.5430 https://www.proquest.com/docview/1901779054 |
Volume | 74 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEF6sQvEiPrFay4JeV02zeZ2k1RYRrOIDegu7yQQrTaNJPPjvndlukF4Ez8uG8M3uvHc-xs7CQPchBBclEKZCqigTodRKJB56p45KHTc10z4n_u2rvJt6U5twq2xbZaMTjaJOi4Ry5BdkuGg2nievPj4FsUZRddVSaLTYRt-RVKbdGI4mj0-_ujh0woYzT0Z-0GanlseEaF7KN_jK01mFP-p4Aqjv89yT1BDd0vn7qqVaVdTG-oy32ZZ1G_lgKecdtgaLXda-t4XxPTYZDGksGX9I6hKKepYCH-Qwp_f36EvyG9K_cz7G2LioZhWfLfhwDkX-jbsFsXckkPJn_HJJ1Gi52mev49HL9a2wVAlCOxhXiijz-qA8YqIKjB3W6AiEfuhmPt5pmqmmNWCok2mIgCpnSaQi5WuNCiuIcP2ArS-KBRwyji6LC8rJZF9h9AQIeeIk0aVMUXI0-77DLhCc-GM5DCM2QYRrHjY3cMYEZ2zgjAnODpMNkP_b1m1Aj-3FquLfY3D09_Ix2zRSNQmTLluvyy84Qf-h1j3WCqZBzx6VH3RRw-k |
link.rule.ids | 315,786,790,12083,21416,27955,27956,31752,33777,43343,43838,74100,74657 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEF6sQvUiPrE-F_S61jSb10nqo1St9WALvYXdZIKVJtEmPfjvnVkTihfB87IhfLM7752PsQvf0x3wwUYJ-LGQKkiEL7USkYPeqaViy47NtM-h2x_Lx4kzqRJuRdVWWetEo6jjPKIceZsMF83Gc-T1x6cg1iiqrlYUGg22Jm1b0jn3Jt5SE_uWXzPmycD1muy8YjEhkpf5GyzSeFrgb1qOAOr6vHQktUM3dPr-2079VtPG9vS22GblNPLuj5S32QpkO6z5XJXFd9mwe0NDyfhLVM4hL6cx8G4KM3p9j54kvyPtO-M9jIzzYlrwacZvZpCnX7hbEHdHBDF_xS_PiRgtVXts3Lsf3fZFRZQgtIVRpQgSpwPKIR4qz1hhjW6A7_p24uKNpolqWgMGOomGAKhuFgUqUK7WqK68ANf32WqWZ3DAODosNigrkR2FsRMg4JEVBVcyRrnR5PsWayM44cfPKIzQhBC2edZcwxkSnKGBMyQ4W0zWQP5v23ENelhdqyJcHoLDv5fP2Hp_9DwIBw_DpyO2YSRsUifHbLWcL-AEPYlSn5rj8g3PVMSJ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEF5sheJFfGJ9Luh1bdNsXidp1eKzCir0FnaTCUaapjb14L93Zt0gXgTPy4bwzew8dmbnY-wkDHQPQnBRAmEqpIoyEUqtROJhdOqo1HFTM-1z5F-9yJuxN7b9T5Vtq6xtojHUaZnQHXmHHBfNxvNkJ7NtEY8Xw7PZuyAGKaq0WjqNBltGL9klGodgHPxY5dAJa_Y8GflBix1bRhMifJm_wkeR5hX-suMJoA7QU09Sa3RDF2-_fdZvk2380HCNrdoAkve_Jb7OlmC6wVr3tkS-yUb9AQ0o4w_JYg7lIk-B9wuY0Et8jCr5BVniCR9illxWecXzKR9MoCw-cbcgHo8EUv6EX54TSVqhttjL8PL5_EpY0gShHcwwRZR5PVAecVIFxiNrDAlCP3QzH083TVfTGjDpyTREQDW0JFKR8rVG0xVEuL7NmtNyCjuMY_DignIy2VOYRwGCnzhJ1JUpypCm4LdZB8GJZ99jMWKTTrjmiXMNZ0xwxgbOmOBsM1kD-b9t-zXosT1iVfyjELt_Lx-xFmpKfHc9ut1jK0bA5hZlnzUX8w84wKBioQ-NtnwB5XPItQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=AB0214%E2%80%85Octreotide+Ameliorates+Dermal+Fibrosis+in+Bleomycin-Induced+Scleroderma&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Orhan%2C+S.O.&rft.au=Yolbas%2C+S.&rft.au=Yildirim%2C+A.&rft.au=Tektemur%2C+A.&rft.date=2015-06-01&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=74&rft.issue=Suppl+2&rft.spage=962&rft_id=info:doi/10.1136%2Fannrheumdis-2015-eular.5430&rft.externalDBID=ttp%3A%2F%2Fard.bmj.com%2Fcontent%2F74%2FSuppl_2%2F962.3.full.pdf |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |